Skip to main content
Premium Trial:

Request an Annual Quote

NorDiag to Buy DNA Sample Prep Firm Genpoint for $13.3M

NEW YORK (GenomeWeb News) – Norwegian cancer diagnostics company NorDiag has signed a deal to buy DNA sample prep company Genpoint, also based in Norway, in a stock deal worth NOK 83.3 million ($13.3 million), NorDiag said last week.
NorDiag said the acquisition will expand its cancer and infectious diagnostics line and will help speed its colorectal cancer test to the market.
Under the agreement, NorDiag will exchange as much as 9.8 million of its own shares to acquire 90.1 percent of Genpoint's outstanding shares. Proceeds from the placement will fund new product roll-out and company growth, NorDiag said.
The company also plans to conduct a rights issue of shares for as much as NOK 10 million after the deal closes.
NorDiag's board will meet to approve the transaction on March 16. It also plans to name Jan Olav Steensland, J. Frode Vaksvik, and Mattias Uhlen as new board members.
Last year, Genpoint worked with NorDiag to help automate and improve NorDiag's DNA isolation capability.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.